Evidence map›Paper›PMID 29151283›Full record

ArticleThe Korean journal of internal medicine2019

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Kyoung Min ChoDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Bhumsuk KeamDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Hyerim HaDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Miso KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Jae-Woo JungDepartment of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Woo-Jung SongDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Tae Min KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Yoon Kyung JeonDepartment of Pathology, Seoul National University Hospital, Seoul, Korea.
Hye-Ryun KangDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Dong-Wan KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Chul Woo KimDepartment of Pathology, Seoul National University Hospital, Seoul, Korea.
Dae Seog HeoDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Funding

Cell Therapy
6 · The paper itself

Abstract

BACKGROUND/

aimsThis study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy.

methodsThe medical records of 326 patients diagnosed with DLBCL were re trospectively analyzed. Both doctor's progress records and nursing records were reviewed. IRR was graded according to the National Cancer Institute Common Terminology Criteria.

resultsIRR was not associated with overall survival (OS) or progression-free survival (PFS) of DLBCL patients as compared to those who did not have IRR (OS: median 78.0 months vs. 69.0 months, p = 0.700; PFS: median 65.4 months vs. 64.0 months, p = 0.901). IRR grade did not affect OS or PFS. B symptoms was independently associated with IRR (hazard ratio [HR], 1.850; 95% confidence interval [CI], 1.041 to 3.290; p = 0.036). Further, bone marrow involvement was independently associated with re-IRR (HR, 4.904; 95% CI, 0.767 to 3.118; p = 0.029).

conclusionOur study shows that IRR of rituximab is not associated with OS or PFS of DLBCL patients who received R-CHOP. Furthermore, our study suggests a need for more careful observation for IRR in patients with B symptoms or bone marrow involvement.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleHumansInfusions, IntravenousInjection Site ReactionLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrednisoneProgression-Free SurvivalCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineCharacteristicsInfusion-related reactionLymphoma, large B-cell, diffusePrognosisRituximab

Identifiers

PMID29151283
PMCPMC6610184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.